Nasdaq: OCG
NEW YORK, Jan. 12, 2026 /PRNewswire/ — Oriental Culture Holding LTD (Nasdaq: OCG) announced today that its Board of Directors has approved a special cash dividend plan to celebrate the company’s fifth anniversary of listing on Nasdaq and reward shareholders for their long-term support.
The specific dividend details are as follows:
OCG CEO Shao Yi stated: “After securing the necessary funds for ongoing operations and development, the company has decided to return a portion of accumulated cash reserves from prior years to shareholders as dividends. This reflects our commitment to rewarding shareholder support and sharing in our growth achievements. This dividend represents our sincere gratitude for shareholders’ five-year partnership. We firmly believe that while actively developing our business, we must also directly reward shareholders to foster long-term value creation.”
This dividend plan was approved by the Board of Directors on January 8, 2026, and its implementation will comply with relevant regulations.
Forward-Looking Statements: This press release contains forward-looking statements. Actual results may differ materially from those expressed or implied due to risks and uncertainties. OCG assumes no obligation to update this information.
View original content:https://www.prnewswire.co.uk/news-releases/oriental-culture-holding-ltd-announces-special-cash-dividend-plan-to-reward-shareholders-on-fifth-anniversary-of-listing-302658164.html
MONACO, May 16, 2026 (GLOBE NEWSWIRE) -- Crypto news is turning toward AlphaPepe after the…
MONACO, May 16, 2026 (GLOBE NEWSWIRE) -- Crypto market news is turning toward AlphaPepe after…
SINGAPORE, May 16, 2026 (GLOBE NEWSWIRE) -- Qoder officially releases version 1.0, upgrading from an…
Patients treated with corabotase showed a rapid onset of action of 0.84 days and peak effect statistically superior to placeboAt Week 24, 60.8% of patients treated with corabotase experienced clinically…
– Complete response (CR) observed in 70% (50/72) of evaluable patients with low-grade upper tract…
- Stenoparib clinical development continues in relapsed small cell lung cancer and, under FDA Fast…